Omnium Global’s vision is to de-risk product commercialization to maximize its impact on global health. Most Life Science startups fail before reaching approvals & having an impact on patients. Omnium helps companies beat these odds by reducing risks, timelines, & costs associated with product commercialization. We do this by working side by side at critical growth points focused on driving immediate results in both commercial and scientific operations. Our track record reflects our expertise, with successful launches of diverse biopharmaceuticals spanning recombinant proteins, vaccines, and cell/gene/oncolytic virus therapies, impacting over 20 countries. We boast >50 approved INDs, 150+ publications & invited conference presentations, and over $750m in commercial agreements closed.